Figures computed from official regulatory filings — .
Analysttarget 45.18 USD (+94%) · consensus 4.75/5 · 11 buy · 1 hold · 0 sell
Ownershipinsiders 1.2% · institutions 128.38% · short 25.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Tango Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
12 buys86 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Crystal Adam | Exercise | $140.4K | SEC |
| Crystal Adam | Sell | $645.6K | SEC |
| Crystal Adam | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Crystal Adam | Sell | $15.2K | SEC |
| Newcomb Jessica | Sell | $122.2K | SEC |
| Newcomb Jessica | Sell | $16K | SEC |
| Newcomb Jessica | Sell | $60.4K | SEC |
| Crystal Adam | Sell | $603.9K | SEC |
| Crystal Adam | Exercise | $140.4K | SEC |
| Crystal Adam | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Crystal Adam | Exercise | $140.4K | SEC |
| Crystal Adam | Sell | $594.4K | SEC |
| Crystal Adam | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Crystal Adam | Sell | $141.1K | SEC |
| Crystal Adam | Sell | $576K | SEC |
| Crystal Adam | Exercise | $140.4K | SEC |
| Crystal Adam | Sell | $222.9K | SEC |
| Crystal Adam | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Azelby Robert | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Azelby Robert | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ketchum John B | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Calhoun Lesley Ann | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lee Sung | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lee Sung | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rothenberg Mace | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |